Daptomycin


Article Author:
Shivali Patel


Article Editor:
Stephen Saw


Editors In Chief:
Amanda Oakley
Jules Lipoff
Shyam Verma


Managing Editors:
Avais Raja
Orawan Chaigasame
Carrie Smith
Abdul Waheed
Khalid Alsayouri
Trevor Nezwek
Radia Jamil
Patrick Le
Anoosh Zafar Gondal
Saad Nazir
William Gossman
Hassam Zulfiqar
Hussain Sajjad
Steve Bhimji
Muhammad Hashmi
John Shell
Matthew Varacallo
Heba Mahdy
Ahmad Malik
Sarosh Vaqar
Mark Pellegrini
James Hughes
Beata Beatty
Beenish Sohail
Nazia Sadiq
Hajira Basit
Phillip Hynes


Updated:
4/4/2019 2:53:54 PM

Indications

Daptomycin is a cyclic lipopeptide antibiotic derived from the organism Streptomyces roseosporus. Daptomycin is used for the treatment of various bacterial infections caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE). Daptomycin has numerous FDA-approved and off-label clinical uses.[1][2][3][4]

FDA-approved clinical uses of daptomycin:

  • Complicated skin and skin structure infections (cSSSI) in adult and pediatric patients
  • S. aureus bacteremia in adult patients including those with right-sided infective endocarditis
  • S. aureus bacteremia in pediatric patients, 1 to 17 years old

Off-label clinical uses of daptomycin include:

  • Diabetic foot infections
  • Left-sided infective endocarditis due to S. aureus or Enterococcus spp. in adult patients
  • Osteomyelitis and/or septic arthritis due to 
  • methicillin-resistant Staphylococcus aureus
  • (MRSA)
  • Native vertebral osteomyelitis
  • Prosthetic joint infection caused by Staphylococci or Enterococci
  • Vancomycin-resistant Enterococcus (VRE) infections

Limitations of Use:

  • Daptomycin is inactivated by pulmonary surfactant and should not be used for the treatment of pneumonia
  • Daptomycin is not recommended in pediatric patients younger than one year of age due to likely effects on the muscular, neuromuscular, and/or nervous systems[5]

Mechanism of Action

Daptomycin is a cyclic lipopeptide antibiotic that exerts its bactericidal effect by disrupting multiple aspects of bacterial cell membrane function. Daptomycin binds to the cell membrane of susceptible organisms and causes a rapid depolarization of membrane potential. The loss of membrane potential leads to the intracellular inhibition of DNA, RNA, and protein synthesis. This ultimately results in bacterial cell death. Daptomycin is only active against gram-positive bacteria.

Administration

Daptomycin is FDA-approved for administration by the intravenous route. It is administered every 24 hours in patients with a creatinine clearance greater than 30 mL/min. The frequency of administration in patients with renal impairment (CrCl less than 30 mL/min) is every 48 hours. The dose of daptomycin required is indication specific. The desired dose should be administered over 30 minutes in adults and children over the age of 7. Daptomycin should be infused over 60 minutes in children one to six years of age. Daptomycin can also be administered as an intravenous push over 2 minutes in adult patients only.[6][7][8]

Pharmacodynamics/Pharmacokinetics:

Route of Administration: Intravenous

Inhibition of bacterial growth: Bactericidal

PK/PD parameter: AUC:MIC

Absorption: Not applicable

The onset of action: Daptomycin has a rapid onset of action

Distribution: Large volume of distribution at steady-state (approximately 1.0 L/kg) in healthy adult patients. The volume of distribution at steady-state in pediatric and critically-ill patients has been found to be significantly lower.

Protein Binding: 90% to 93%; 84% to 88% in patients with a creatine clearance less than 30 mL/min.

Metabolism: Minimal amounts of oxidative metabolites have been detected. In vitro studies suggest human liver microsomes do not metabolize daptomycin.

Clearance: 8.3 to 9 mL/min/kg in adults with normal renal function. Increased clearance has been demonstrated in pediatric patients.

Half-life: 8 to 9 hours in healthy adults with normal renal function. The elimination half-life can be significantly prolonged in patients with renal impairment (up to 28 hours). Shorter elimination half-life has been noted in pediatric patients.

Excretion: Daptomycin is primarily eliminated as unchanged drug in the urine (78%) with a lesser amount eliminated in feces (5.7%).

Adverse Effects

Adverse effects associated with daptomycin therapy include myopathy/rhabdomyolysis, eosinophilic pneumonia, and anaphylactic hypersensitivity reactions. Patients may also experience less severe adverse effects such as constipation, headache, insomnia, and skin rash.

Daptomycin is associated with an increased incidence of myopathy and rhabdomyolysis. Cases have been reported in patients with and without acute renal failure. Therefore weekly monitoring of creatine phosphokinase (CPK) levels is recommended in patients receiving daptomycin therapy. More frequent monitoring is recommended in patients with renal impairment and/or those receiving concomitant HMG CoA reductase inhibitors (statins). Treatment should be discontinued in patients with signs and symptoms of myopathy in conjunction with an elevated CPK (greater than five times ULN or greater than 1000 units/L) and in asymptomatic patients with a CPK elevation greater than ten times ULN (greater than 2000 units/L). The incidence of myopathy has been shown to increase with administration of greater than the recommended dosage. Additionally, providers should consider temporarily discontinuing other agents associated with rhabdomyolysis (e.g., HMG-CoA reductase inhibitors) during daptomycin therapy.

Daptomycin therapy is also associated with the development of eosinophilic pneumonia, which generally occurs 2 to 4 weeks after initiating therapy. Patients should be monitored for signs and symptoms of eosinophilic pneumonia, including new onset or worsening fever, and new infiltrate on chest imaging. Daptomycin therapy should be immediately discontinued for patients who experience signs and symptoms of eosinophilic pneumonia, and appropriate treatment should be initiated. It is important to note that the incidence of eosinophilic pneumonia may reoccur with re-exposure to daptomycin.

Rare cases of peripheral neuropathy have been observed in patients receiving daptomycin. Monitoring for new onset or worsening neuropathy is recommended.

It is important to note that prolonged use of daptomycin can lead to the development of a superinfection such as Clostridium difficile-associated diarrhea (CDAD) and pseudomembranous colitis. The incidence of CDAD has been observed greater than two months after treatment with daptomycin.

Contraindications

Daptomycin is contraindicated in patients with a known hypersensitivity reaction to the drug or any component within the formulation.

Clinical Considerations

Although daptomycin does not have other contraindications to its use, there are important clinical considerations to keep in mind when caring for patients.

Geriatric

Elderly patients are at an increased risk of daptomycin toxicity due to age-related changes in renal function or factors that may enhance the exposure to the medication. However, no dosage adjustments are recommended for patients with a creatinine clearance  greater than 30 mL/min.

Pregnancy

Daptomycin is pregnancy category B; however, there is still limited information available on the use of daptomycin during pregnancy. Case reports describe the successful use of daptomycin during second and third trimesters of pregnancy. Additionally, animal reproductive studies have not yet determined any evidence of fetal harm from maternal use of daptomycin. Nevertheless, a risk-benefit analysis should be conducted before initiating daptomycin in pregnant patients.

Breastfeeding

Low concentrations of daptomycin have been detected in breast milk (0.1% of the maternal dose). Currently, there is no information available on the effects of daptomycin on breastfed infants or milk production. Like other antibiotics, maternal use of daptomycin may cause a non-dose related change in bowel flora. Therefore, breastfed infants should be monitored for gastrointestinal disturbances. Breastfeeding mothers who are receiving treatment with daptomycin should be advised to consult with their provider and conduct a risk-benefit analysis prior to breastfeeding.

Renal Impairment

Reduced renal function can lead to accumulation of daptomycin, thereby increasing the risk of adverse effects. Dose adjustments are necessary for patients with a creatinine clearance less than 30 mL/min, including patients receiving hemodialysis or continuous ambulatory peritoneal dialysis (CAPD). It is recommended that renal function and creatinine phosphokinase (CPK) levels be monitored multiple times a week in patients with renal impairment.

Bacterial Resistance

Like with other antibiotics, prolonged or inappropriate treatment with daptomycin can lead to bacterial resistance. It is important for providers to be aware of increased antibiotic resistance patterns and practice appropriate antimicrobial stewardship. Patients should be counseled on the importance of medication adherence to prevent the development of multidrug-resistant infections.

Drug Interactions

Other medications taken along with daptomycin may increase the risk of adverse effects and drug toxicity. Therefore dosing adjustments, additional monitoring, and consideration of alternative treatment should be considered when combining daptomycin with certain medications. Caution is advised when administering daptomycin with HMG-CoA reductase inhibitors, (statins) as this can potentially increase the risk of skeletal muscle toxicity. It is recommended that administration of HMG-CoA reductase inhibitors be temporarily discontinued while patients receive treatment with daptomycin. If the concomitant administration cannot be avoided, close monitoring of creatinine phosphokinase should be instated at least once-weekly.

Monitoring

Patients receiving daptomycin therapy should be monitored to ensure safe administration of the medication. Baseline renal function tests are recommended to assess the presence of renal impairment and necessity of dosage adjustments. Additionally, it is recommended that clinicians obtain baseline creatinine phosphokinase (CPK) levels in patients requiring treatment for greater than 1 week. After that, the CPK should be monitored at least once-weekly. More frequent monitoring of CPK is necessary for patients with current or prior statin therapy, an unexplained elevation in CPK, or renal impairment.

Patients should also be monitored for muscle pain or weakness, new onset or worsening peripheral neuropathy, and signs or symptoms of eosinophilic pneumonia. Furthermore, patients who develop diarrhea should be tested for C. difficile infection.

Toxicity

Potentially serious adverse drug events associated with daptomycin therapy include eosinophilic pneumonia and myopathy/rhabdomyolysis.

Enhancing Healthcare Team Outcomes

Healthcare workers including intensivist, infectious disease specialists, internists and nurse practitioners who prescribe daptomycin should monitor the patient to ensure safe administration of the medication. Baseline renal function tests are recommended to assess the presence of renal impairment and the necessity of dosage adjustments. Additionally, it is recommended that clinicians obtain baseline creatinine phosphokinase (CPK) levels in patients requiring treatment for greater than 1 week. After that, the CPK should be monitored at least once-weekly. More frequent monitoring of CPK is necessary for patients with current or prior statin therapy, an unexplained elevation in CPK, or renal impairment. An interdisciplinary team of specialty trained nurses, pharmacists, and clinicians monitoring treatment will provide the best outcomes. [Level V]

Patients should also be monitored for muscle pain or weakness, new onset or worsening peripheral neuropathy, and signs or symptoms of eosinophilic pneumonia. Furthermore, patients who develop diarrhea should be tested for C. difficile infection.


Interested in Participating?

We are looking for contributors to author, edit, and peer review our vast library of review articles and multiple choice questions. In as little as 2-3 hours you can make a significant contribution to your specialty. In return for a small amount of your time, you will receive free access to all content and you will be published as an author or editor in eBooks, apps, online CME/CE activities, and an online Learning Management System for students, teachers, and program directors that allows access to review materials in over 500 specialties.

Improve Content - Become an Author or Editor

This is an academic project designed to provide inexpensive peer-reviewed Apps, eBooks, and very soon an online CME/CE system to help students identify weaknesses and improve knowledge. We would like you to consider being an author or editor. Please click here to learn more. Thank you for you for your interest, the StatPearls Publishing Editorial Team.

Daptomycin - Questions

Take a quiz of the questions on this article.

Take Quiz
Typically, how often are creatine phosphokinase (CPK) levels monitored during daptomycin therapy?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
What type of infection is daptomycin used to treat?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
By which route is daptomycin administered?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
Which of the following medications interact with daptomycin?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
A 75-year-old chronically ill male is admitted to the intensive care unit for septic shock for presumed vancomycin-resistant enterococci (VRE) bacteremia and is started on daptomycin. Seven days into treatment the patient reports severe muscle aches. What is the appropriate lab test to order to determine the etiology of the patient’s pain?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up

Daptomycin - References

References

Tascini C,Sbrana F,Sozio E,Dal Pino B,Bertolino G,Ripoli A,Pallotto C,Emdin M,Sampietro T, Statins during daptomycin therapy: to give or not to give? Minerva anestesiologica. 2019 Jan 4;     [PubMed]
Bricca R,Goutelle S,Roux S,Gagnieu MC,Becker A,Conrad A,Valour F,Laurent F,Triffault-Fillit C,Chidiac C,Ferry T, Genetic polymorphisms of ABCB1 (P-glycoprotein) as a covariate influencing daptomycin pharmacokinetics: a population analysis in patients with bone and joint infection. The Journal of antimicrobial chemotherapy. 2019 Jan 9;     [PubMed]
Jiang JH,Dexter C,Cameron DR,Monk IR,Baines S,Abbott IJ,Spelman DW,Kostoulias X,Nethercott C,Howden BP,Peleg AY, Evolution of daptomycin resistance in coagulase negative staphylococci involves mutations of the essential two component regulator WalKR. Antimicrobial agents and chemotherapy. 2019 Jan 7;     [PubMed]
Piva S,Di Paolo A,Galeotti L,Ceccherini F,Cordoni F,Signorini L,Togni T,De Nicolò A,Rasulo FA,Fagoni N,Latronico N,D'Avolio A, Daptomycin Plasma and CSF Levels in Patients with Healthcare-Associated Meningitis. Neurocritical care. 2019 Jan 3;     [PubMed]
Wasko JA,Dietrich E,Davis K, Risk of Daptomycin Associated Myopathy with Concomitant Statin Use. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2018 Dec 28;     [PubMed]
Hagiya H,Sugawara Y,Kimura K,Hamaguchi S,Nishi I,Hayashi M,Akeda Y,Tomono K, Emergence of daptomycin non-susceptible coagulase-negative Staphylococci in patients with cardiovascular device infections: Two cases report investigated by whole genome analysis. Medicine. 2018 Dec;     [PubMed]
Leong HN,Kurup A,Tan MY,Kwa ALH,Liau KH,Wilcox MH, Management of complicated skin and soft tissue infections with a special focus on the role of newer antibiotics. Infection and drug resistance. 2018;     [PubMed]
Sipahi OR,Kahraman H,Erdem HA,Yetkin F,Kaya S,Demirdal T,Tunccan OG,Karasahin O,Oruc E,Cag Y,Kurtaran B,Ulug M,Kutlu M,Avci M,Oztoprak N,Arda B,Pullukcu H,Tasbakan M,Yamazhan T,Kandemir O,Dizbay M,Sipahi H,Ulusoy S, Daptomycin vs. glycopeptides in the treatment of febrile neutropenia: results of the Izmir matched cohort study. Infection. 2018 Nov 29;     [PubMed]

Disclaimer

The intent of StatPearls is to provide practice questions and explanations to assist you in identifying and resolving knowledge deficits. These questions and explanations are not intended to be a source of the knowledge base of all of medicine, nor is it intended to be a board or certification review of Dermatology. The authors or editors do not warrant the information is complete or accurate. The reader is encouraged to verify each answer and explanation in several references. All drug indications and dosages should be verified before administration.

StatPearls offers the most comprehensive database of free multiple-choice questions with explanations and short review chapters ever developed. This system helps physicians, medical students, dentists, nurses, pharmacists, and allied health professionals identify education deficits and learn new concepts. StatPearls is not a board or certification review system for Dermatology, it is a learning system that you can use to help improve your knowledge base of medicine for life-long learning. StatPearls will help you identify your weaknesses so that when you are ready to study for a board or certification exam in Dermatology, you will already be prepared.

Our content is updated continuously through a multi-step peer review process that will help you be prepared and review for a thorough knowledge of Dermatology. When it is time for the Dermatology board and certification exam, you will already be ready. Besides online study quizzes, we also publish our peer-reviewed content in eBooks and mobile Apps. We also offer inexpensive CME/CE, so our content can be used to attain education credits while you study Dermatology.